A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy

Adoptive cell therapy using chimeric antigen receptor (CAR)-engineered T cells has emerged as a very promising approach to combating cancer. Despite its ability to eliminate tumors shown in some clinical trials, CAR-T cell therapy involves some significant safety challenges, such as cytokine release syndrome (CRS) and “on-target, off-tumor” toxicity, which is related to poor control of the dose, location, and timing of T cell activity. In the past few years, some strategies to avoid the side effects of CAR-T cell therapy have been reported, including suicide gene, inhibitory CAR, dual-antigen receptor, and the use of exogenous molecules as switches to control the CAR-T cell functions. Because of the advances of the CAR paradigm and other forms of cancer immunotherapy, the most effective means of defeating the cancer has become the integration therapy with the combinatorial control system of switchable dual-receptor CAR-T cell and immune checkpoint blockade.

• Publication year

  2017

• Venue

  Journal of Hematology & Oncology

• Publication date

  2017-01-03

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1186/s13045-016-0379-6PMID 28049484PMCID 5210295
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Journal of Hematology & Oncology

  2019cited by this paper
• Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy

  2016cited by this paper
• Engineering Customized Cell Sensing and Response Behaviors Using Synthetic Notch Receptors.

  2016influential reference
• Versatile strategy for controlling the specificity and activity of engineered T cells

  2016cited by this paper
• Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies

  2016cited by this paper
• A Receptor for All Occasions.

  2016influential reference
• Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma.

  2016cited by this paper
• Immunotherapy: Two antigens are better than one

  2016cited by this paper
• Design of chimeric antigen receptors with integrated controllable transient functions

  2016cited by this paper
• Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits.

  2016influential reference
• Programming of donor T cells using allogeneic δ-like ligand 4-positive dendritic cells to reduce GVHD in mice.

  2016cited by this paper
• Therapeutic Potential of T Cell Chimeric Antigen Receptors (CARs) in Cancer Treatment: Counteracting Off-Tumor Toxicities for Safe CAR T Cell Therapy.

  2016cited by this paper
• Adoptive T Cell Therapies: A Comparison of T Cell Receptors and Chimeric Antigen Receptors.

  2016cited by this paper
• Safety and Response of Incorporating CD19 Chimeric Antigen Receptor T Cell Therapy in Typical Salvage Regimens for Children and Young Adults with Acute Lymphoblastic Leukemia

  2015cited by this paper
• Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T-lymphocytes

  2015cited by this paper
• Chimeric Antigen Receptor– and TCR-Modified T Cells Enter Main Street and Wall Street

  2015cited by this paper
• An Inducible Caspase-9 Suicide Gene to Improve the Safety of Therapy Using Human Induced Pluripotent Stem Cells.

  2015cited by this paper
• T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.

  2015cited by this paper
• Polycomb repressive complex 2 component Suz12 is required for hematopoietic stem cell function and lymphopoiesis.

  2015cited by this paper
• Chimeric Antigen Receptor Engineering: A Right Step in the Evolution of Adoptive Cellular Immunotherapy

  2015cited by this paper
• Engineering CAR-T cells: Design concepts.

  2015cited by this paper
• IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo

  2015cited by this paper
• Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells.

  2015cited by this paper
• Remote control of therapeutic T cells through a small molecule–gated chimeric receptor

  2015cited by this paper
• Adoptive cell transfer as personalized immunotherapy for human cancer

  2015cited by this paper
• Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation.

  2015cited by this paper
• Redirection of genetically engineered CAR-T cells using bifunctional small molecules.

  2015cited by this paper
• CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia.

  2015cited by this paper
• Anti-CD20/CD3 T cell–dependent bispecific antibody for the treatment of B cell malignancies

  2015cited by this paper
• CAR-T field booms as next-generation platforms attract big players

  2015cited by this paper
• Targeting heparanase overcomes chemoresistance and diminishes relapse in myeloma

  2015cited by this paper
• CD28z CARs and Armored CARs

  2014cited by this paper
• Molecular architecture of the αβ T cell receptor–CD3 complex

  2014cited by this paper
• Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia

  2014cited by this paper
• Cytokine release syndrome in cancer immunotherapy with chimeric antigen receptor engineered T cells.

  2014cited by this paper
• Checkpoint Blockade Cancer Immunotherapy Targets Tumour-Specific Mutant Antigens

  2014cited by this paper
• Clinical application of genetically modified T cells in cancer therapy

  2014cited by this paper
• Challenges to chimeric antigen receptor (CAR)-T cell therapy for cancer.

  2014cited by this paper
• Novel Approaches to Enhance the Specificity and Safety of Engineered T Cells

  2014cited by this paper
• Chimeric antigen receptor T cells for sustained remissions in leukemia.

  2014cited by this paper
• Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies

  2014cited by this paper
• Current concepts in the diagnosis and management of cytokine release syndrome.

  2014cited by this paper
• Chimeric antigen receptor therapy for cancer.

  2014cited by this paper
• Immune Escape Mechanisms as a Guide for Cancer Immunotherapy

  2014cited by this paper
• Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer

  2014cited by this paper
• Engineered T cells for cancer therapy

  2014cited by this paper
• PD-1– and CTLA-4–Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy Responses

  2013cited by this paper
• CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia

  2013cited by this paper
• Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology.

  2013cited by this paper
• Chimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challenges

  2013cited by this paper
• Bispecific small molecule–antibody conjugate targeting prostate cancer

  2013cited by this paper
• Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity.

  2013cited by this paper
• Targeting T cells to tumor cells using bispecific antibodies.

  2013cited by this paper
• Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia.

  2013cited by this paper
• Efficacy and safety of adoptive immunotherapy using anti-CD19 chimeric antigen receptor transduced T-cells: a systematic review of phase I clinical trials

  2013cited by this paper
• The basic principles of chimeric antigen receptor design.

  2013cited by this paper
• Gene-engineered T cells for cancer therapy

  2013cited by this paper
• Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.

  2013cited by this paper
• Engineered T cells for anti-cancer therapy.

  2012cited by this paper
• Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells

  2012cited by this paper
• Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning.

  2012cited by this paper
• B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.

  2012cited by this paper
• CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results.

  2012cited by this paper
• CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe.

  2012cited by this paper
• Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.

  2012cited by this paper
• Dual Targeting of ErbB2 and MUC1 in Breast Cancer Using Chimeric Antigen Receptors Engineered to Provide Complementary Signaling

  2012cited by this paper
• Trial Watch

  2012cited by this paper
• Adoptive immunotherapy for cancer: harnessing the T cell response

  2012cited by this paper
• Advances in graft-versus-host disease biology and therapy

  2012cited by this paper
• Seventeen-gene signature from enriched Her2/Neu mammary tumor-initiating cells predicts clinical outcome for human HER2+:ERα− breast cancer

  2012cited by this paper
• The blockade of immune checkpoints in cancer immunotherapy

  2012cited by this paper
• Inducible apoptosis as a safety switch for adoptive cell therapy.

  2011influential reference
• IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression.

  2011cited by this paper
• Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.

  2011cited by this paper
• Cancer immunotherapy comes of age

  2011cited by this paper
• Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias.

  2011cited by this paper
• An Inducible Caspase 9 Suicide Gene to Improve the Safety of Mesenchymal Stromal Cell Therapies

  2010cited by this paper
• Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2.

  2010cited by this paper
• Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study.

  2009cited by this paper
• Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen.

  2009cited by this paper
• Graft-versus-host disease.

  2009cited by this paper
• Tumor escape mechanism governed by myeloid-derived suppressor cells.

  2008cited by this paper
• Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes.

  2007cited by this paper
• Human TCR-Binding Affinity is Governed by MHC Class Restriction1

  2007cited by this paper
• Graft-versus-host disease

  2007cited by this paper
• How TCRs bind MHCs, peptides, and coreceptors.

  2006cited by this paper
• An inducible caspase 9 safety switch for T-cell therapy.

  2005cited by this paper
• IL-13受体α2降低血吸虫病肉芽肿的炎症反应并延长宿主存活时间[英]/Mentink-Kane MM,Cheever AW，Thompson RW，et al//Proc Natl Acad Sci U S A

  2005cited by this paper
• CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms

  2004cited by this paper
• Dynamics of cell surface molecules during T cell recognition.

  2003cited by this paper
• Cancer immunoediting: from immunosurveillance to tumor escape

  2002cited by this paper
• Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor

  2002cited by this paper
• Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft.

  2001cited by this paper
• A high-dose pulse steroid regimen for controlling active chronic graft-versus-host disease.

  2001cited by this paper
• Fidelity of T cell activation through multistep T cell receptor zeta phosphorylation.

  1998cited by this paper
• HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia.

  1997cited by this paper
• T–cell mediated rejection of gene–modified HIV–specific cytotoxic T lymphocytes in HIV–infected patients

  1996cited by this paper
• Ganciclovir treatment of herpes simplex thymidine kinase-transduced primary T lymphocytes: an approach for specific in vivo donor T-cell depletion after bone marrow transplantation?

  1994cited by this paper
• Mini Review Article

  year unknowncited by this paper

• Noncoding RNAs: A Novel Frontier in Liver Cancer Research and Therapy: Implications for Precision Oncology.

  2026cites this paper
• Emerging roles of non-coding RNA derived from extracellular vesicles in regulating PD-1/PD-L1 pathway: insights into cancer immunotherapy and clinical applications

  2025cites this paper
• An overview on in-vivo generation of CAR-T cells using CRISPR-loaded functionalized nanocarriers for treating B-cell lineage acute lymphoblastic leukemia

  2025cites this paper
• A critical review of the synergistic potential of targeting p53 and CAR T cell therapy in cancer treatment.

  2025cites this paper
• Identification of Prognostic-Related Genes in Acute Myeloid Leukemia: A Study Based on TCGA Data Analysis.

  2025cites this paper
• Targeting cancer stem cells with CAR-based immunotherapy: biology, evidence, and future directions

  2025cites this paper
• Streptococcus gallolyticus supernatant induces M2 macrophage polarization and activates IL-17 F signaling in colorectal tumorigenesis

  2025cites this paper
• Design and Evaluation of Albumin‐Based Surface Functionalized Nanoparticles for Targeting Breast Cancer

  2025cites this paper
• Recent Progress in Poly(ADP–Ribose) Polymerase‐1 Inhibitors for Application in Cancer

  2025cites this paper
• Cellular senescence in the tumor with a bone niche microenvironment: friend or foe?

  2025cites this paper
• Extracellular Vesicle‐Based Antitumor Nanomedicines

  2025cites this paper
• Tumor-infiltrating myeloid cells; mechanisms, functional significance, and targeting in cancer therapy

  2025cites this paper
• Advances in dendritic cell-based therapeutic tumor vaccines.

  2025cites this paper
• New approaches of chimeric antigen receptor (CAR)-immune cell-based therapy in gastric cancer; highlight CAR-T and CAR-NK

  2025cites this paper
• Advancements in Osteosarcoma Therapy: Overcoming Chemotherapy Resistance and Exploring Novel Pharmacological Strategies

  2025cites this paper
• Abscopal Effects and Immunomodulation in Skin Cancer Therapy

  2025cites this paper
• Extranodal natural killer/T-cell lymphoma coexisting with peripheral T-cell lymphoma, not otherwise specified

  2024cites this paper
• Neoadjuvant Chemotherapy for Adults with Osteogenic Sarcoma

  2024cites this paper
• Recent advancements in improving the efficacy and safety of chimeric antigen receptor (CAR)-T cell therapy for hepatocellular carcinoma

  2024cites this paper
• Role of Interleukins in Pancreatic Cancer: A Literature Review

  2024cites this paper
• Bayesian network analysis of risk classification strategies in the regulation of cellular products

  2024cites this paper
• Nanotechnology‐Fortified Manipulation of Cell Ca2+ Signaling

  2024cites this paper
• The Unprecedented Success of Chimeric Antigen Receptor T-Cell Therapy in the Treatment of Hematological Malignancies

  2024cites this paper
• Bridging barriers: advances and challenges in modeling biological barriers and measuring barrier integrity in organ-on-chip systems.

  2024cites this paper
• Tumour‐derived exosome SNHG17 induced by oestrogen contributes to ovarian cancer progression via the CCL13–CCR2–M2 macrophage axis

  2024cites this paper
• Exosomes and breast cancer angiogenesis; Highlights in intercellular communication

  2024cites this paper
• Prenatal Ruxolitinib Treatment Improved Muscle Strength but Showed No Impact on the Neurobehavioral and Electrophysiological Traits in Adult Mice

  2024cites this paper
• Cytokine-based models for efficient differentiation between infection and cytokine release syndrome in patients with hematological malignancies

  2024cites this paper
• Directed targeting of B-cell maturation antigen-specific CAR T cells by bioinformatic approaches: From in-silico to in-vitro.

  2023cites this paper
• Programmed death-ligand 1 expression in diffuse large B-cell lymphoma is associated with poor prognosis

  2023cites this paper
• Recent Insights into the Angioregulatory Role of Long Non-coding RNAs and Circular RNAs in Gliomas: From Signaling Pathways to Clinical Aspects.

  2023cites this paper
• Thrombotic Microangiopathy After Hematopoietic Stem Cell and Solid Organ Transplantation: A Review for Intensive Care Physicians

  2023cites this paper
• Interleukin-1 Receptor Accessory Protein (IL-1RAP): A Magic Bullet Candidate for Immunotherapy of Human Malignancies.

  2023cites this paper
• The relationship between DNA methyltransferase 3B (DNMT3B) and miR 124-3pa expressions in bladder cancer tissues

  2023cites this paper
• The Interaction between Macrophages and Triple‐negative Breast Cancer Cells Induces ROS‐Mediated Interleukin 1α Expression to Enhance Tumorigenesis and Metastasis

  2023cites this paper
• Advancement in precision diagnosis and therapeutic for triple-negative breast cancer: Harnessing diagnostic potential of CRISPR-cas & engineered CAR T-cells mediated therapeutics.

  2023cites this paper
• NK cell defects: implication in acute myeloid leukemia

  2023cites this paper
• Spotlight on CYP4B1

  2023cites this paper
• Reversing chemokine/chemokine receptor mismatch to enhance the antitumor efficacy of CAR-T cells.

  2022cites this paper
• Bone marrow-targetable Green Tea Catechin-Based Micellar Nanocomplex for synergistic therapy of Acute myeloid leukemia

  2022cites this paper
• A glimpse of research cores and frontiers on the relationship between long noncoding RNAs (lncRNAs) and colorectal cancer (CRC) using the VOSviewer tool

  2022cites this paper
• Current updates on generations, approvals, and clinical trials of CAR T-cell therapy

  2022influential citation
• The potential therapeutic effect of klotho on cell viability in human colorectal adenocarcinoma HT-29 cells

  2022cites this paper
• The neuronal protein Neuroligin 1 promotes colorectal cancer progression by modulating the APC/β-catenin pathway

  2022cites this paper
• Targeting macrophages in hematological malignancies: recent advances and future directions

  2022cites this paper
• Glycosylated modification of MUC1 maybe a new target to promote drug sensitivity and efficacy for breast cancer chemotherapy

  2022cites this paper
• Potential mechanisms of quercetin in cancer prevention: focus on cellular and molecular targets

  2022cites this paper
• Recent achievements in nano-based technologies for ocular disease diagnosis and treatment, review and update

  2022cites this paper
• Protective effect of berberine against LPS-induced injury in the intestine: a review

  2022cites this paper
• Colorectal cancer-derived exosomes and modulation KRAS signaling

  2022cites this paper
• Bio-nano scale modifications of melittin for improving therapeutic efficacy

  2022cites this paper
• Identification of miR-195-5p as a novel prognostic biomarker for colorectal cancer

  2022cites this paper
• Neutrophils and polymorphonuclear myeloid-derived suppressor cells: an emerging battleground in cancer therapy

  2022cites this paper
• The Current State of Treatment and Future Directions in Cutaneous Malignant Melanoma

  2022cites this paper
• Melanoma therapeutics: a literature review

  2022influential citation
• Advancement in Nanomaterial Synthesis and its Biomedical Applications

  2022cites this paper
• Overview of liquid biopsy

  2022cites this paper
• Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor (CAR) for tumor immunotherapy; recent progress

  2022cites this paper
• Circular RNAs and glioblastoma multiforme: focus on molecular mechanisms

  2022cites this paper
• The roles and therapeutic approaches of MSC-derived exosomes in colorectal cancer

  2022cites this paper
• Evaluation of exosomal non-coding RNAs in cancer using high-throughput sequencing

  2022cites this paper
• Cancer exosomes and natural killer cells dysfunction: biological roles, clinical significance and implications for immunotherapy

  2022cites this paper
• LncRNA TP73‐AS1 promotes nasopharyngeal carcinoma progression through targeting miR-342-3p and M2 polarization via exosomes

  2022cites this paper
• Engineered T cells and their therapeutic applications in autoimmune diseases

  2022cites this paper
• Strategies to overcome the side effects of chimeric antigen receptor T cell therapy

  2022cites this paper
• Nanomedicine-based cancer immunotherapies developed by reprogramming tumor-associated macrophages.

  2021cites this paper
• Cellular based immunotherapy for primary liver cancer

  2021cites this paper
• Transient prenatal ruxolitinib treatment suppresses astrogenesis during development and improves learning and memory in adult mice

  2021cites this paper
• Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients

  2021cites this paper
• CAR T Cells.

  2021cites this paper
• Unmanipulated haploidentical donor and matched unrelated donor hematopoietic stem cell transplantation in patients with paroxysmal nocturnal hemoglobinuria: a single-center study

  2021cites this paper
• Sentinel Lymph Node Biopsy Positivity in Patients With Acral Lentiginous and Other Subtypes of Cutaneous Melanoma.

  2021cites this paper
• CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies

  2021cites this paper
• MicroRNA-142-5p Suppresses Proliferation and Invasion of Non-Small Cell Lung Cancer Cells by Targeting Programmed Cell Death Receptor Ligand 1

  2021cites this paper
• Can the Mitochondrial Metabolic Theory Explain Better the Origin and Management of Cancer than Can the Somatic Mutation Theory?

  2021cites this paper
• The effect of low serum calcium level on the severity and mortality of Covid patients: A systematic review and meta‐analysis

  2021cites this paper
• Viper venoms drive the macrophages and hepatocytes to sequester and clear platelets: novel mechanism and therapeutic strategy for venom-induced thrombocytopenia

  2021cites this paper
• Bioactive Molecules Derived from Snake Venoms with Therapeutic Potential for the Treatment of Thrombo-Cardiovascular Disorders Associated with COVID-19

  2021cites this paper
• Thrombosis in COVID-19 infection: Role of platelet activation-mediated immunity

  2021cites this paper
• Circular RNA hsa_circ_0044234 as distinct molecular signature of triple negative breast cancer: a potential regulator of GATA3

  2021cites this paper
• Prognostic relevance of remission and measurable residual disease status in AML patients prior to reduced intensity or non-myeloablative allogeneic stem cell transplantation

  2021cites this paper
• Vector engineering, strategies and targets in cancer gene therapy

  2021cites this paper
• CAR T-Cell Therapy: The Next Frontier for Cancer Immunotherapy

  2021cites this paper
• Remote controlling of CAR-T cells and toxicity management: Molecular switches and next generation CARs

  2021cites this paper
• Efficacy and tolerability of Janus kinase inhibitors in myelofibrosis: a systematic review and network meta-analysis

  2021cites this paper
• Cell Therapies in Bladder Cancer Management

  2021cites this paper
• Selenium Attenuates S. aureus-Induced Inflammation by Regulation TLR2 Signaling Pathway and NLRP3 Inflammasome in RAW 264.7 Macrophages

  2021cites this paper
• Engineering Metabolism of Chimeric Antigen Receptor (CAR) Cells for Developing Efficient Immunotherapies

  2021cites this paper
• Prognostic significance and targeting tumor-associated macrophages in cancer: new insights and future perspectives

  2021cites this paper
• Acute Tubulointerstitial Nephritis in Clinical Oncology: A Comprehensive Review

  2021cites this paper
• Immunotherapy and Its Development for Gynecological (Ovarian, Endometrial and Cervical) Tumors: From Immune Checkpoint Inhibitors to Chimeric Antigen Receptor (CAR)-T Cell Therapy

  2021cites this paper
• Selecting the Optimal CAR-T for the Treatment of B-Cell Malignancies

  2021cites this paper
• Chitinases and chitinase-like proteins as biomarkers in neurologic disorders

  2020cites this paper
• Modulating transcription factor activity: Interfering with protein-protein interaction networks.

  2020cites this paper
• CAR-T Cells for Cancer Treatment: Current Design and Next Frontiers.

  2020cites this paper
• MRI radiomics for early prediction of response to vaccine therapy in a transgenic mouse model of pancreatic ductal adenocarcinoma

  2020cites this paper
• A brief history of CAR-T cells: from laboratory to the bedside

  2020cites this paper
• Metastasis-associated fibroblasts promote angiogenesis in metastasized pancreatic cancer via the CXCL8 and the CCL2 axes

  2020cites this paper
• A systematic review of salvage therapies in refractory metastatic colorectal cancer

  2020cites this paper
• CAR T-Cells.

  2020cites this paper